Plural Chalcogens Bonded Directly To The Hetero Ring Patents (Class 549/400)
  • Patent number: 9790536
    Abstract: Methods for assaying ?-L-iduronidase enzymatic activity and methods for screening newborns for Mucopolysaccharidosis Type-I.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: October 17, 2017
    Assignee: University of Washington
    Inventors: Michael H. Gelb, Sophie Blanchard
  • Patent number: 9675580
    Abstract: Provided is a composition containing myricetin or a pharmaceutically available salt thereof as an active ingredient. The composition increases exercise capacity and enhances physical strength. In addition, the composition prevents aging and recovers from fatigue. The composition increases energy efficiency by improving the function of mitochondria, and also has an antiobesity effect by increasing energy consumption. Therefore, the composition may be significantly applied in a functional food or medicine field.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: June 13, 2017
    Inventor: Kyong-Tai Kim
  • Patent number: 9206152
    Abstract: The present invention provides a method for extracting dihydroquercetin from roots of larch trees in a specific region by utilizing a resource advantage that the roots (200 mm below the earth surface) of tree species has a relatively high content of dihydroquercetin. The method includes steps of: selecting raw material, processing, extracting, concentrating, hydrolyzing, further extracting and recrystallizing. The present invention has researched and established a process with optimized environmental protection and indexes to fill the gap in domestic industrialized extraction process by utilizing the resource advantage that the roots of tree species has relatively high content of dihydroquercetin.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: December 8, 2015
    Inventor: Liqian Shen
  • Publication number: 20150133493
    Abstract: Compounds including those of the Formula I where X, R1, R2 and subscript t are as defined herein, useful as ?-secretase inhibitors, are provided, as are compositions comprising the compounds, as well as methods for use of the compounds for treating or preventing neurodegenerative diseases, such as, for instance, Alzheimer's disease.
    Type: Application
    Filed: July 3, 2014
    Publication date: May 14, 2015
    Inventors: Lei Zhu, Hakim Djaballah, Yueming Li, Christopher Chad Shelton
  • Patent number: 9012663
    Abstract: Methods for assaying ?-L-iduronidase enzymatic activity and methods for screening newborns for Mucopolysaccharidosis Type-I.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: April 21, 2015
    Assignee: University of Washington
    Inventors: Michael H. Gelb, Sophie Blanchard
  • Publication number: 20150080566
    Abstract: The invention relates to a process for the extraction of wood, comprising the following steps: providing wood particles, at least a first class and a second class, stacking a fine layer consisting of the first class wood particles over a further layer consisting of the second class wood particles, and extracting the wood particles using a liquid extractant, in which the extractant flows from the top downwards, first through the fine layer and then through the further layer, in which the wood particles of the first class are finer than the wood particles of the second class, and thus the fine layer has a lower permeability than the further layer.
    Type: Application
    Filed: February 2, 2012
    Publication date: March 19, 2015
    Applicant: LDA AG
    Inventor: Franz Wiesbeck
  • Publication number: 20150080587
    Abstract: The invention relates to a process for the manufacture of taxifolin, comprising the following steps: stacking the wood particles in a percolator, extracting the wood particles in the percolator using ethanol to dissolve at least resins, oils, and taxifolin, discharging the ethanolic extract from the percolator, and purifying the ethanolic extract for the manufacture of taxifolin with the following steps in the specified order: preparing a mixture of water and the ethanolic extract, mixing the mixture at between 70° C. and 99° C. so that taxifolin in the aqueous phase of the mixture goes into the solution, cooling the mixture to below 65° C. for separating and removing the resin phase and the oil phase from the water phase, adding taxifolin seed crystals to the water phase, temperature controlling the water phase at between 0° C. and 30° C. for the crystallisation of taxifolin, and separating the crystallised taxifolin from the mother liquor.
    Type: Application
    Filed: February 2, 2012
    Publication date: March 19, 2015
    Applicant: LDA AG
    Inventor: Franz Wiesbeck
  • Publication number: 20150080461
    Abstract: The present invention relates to a composition having antiviral activity for prophylaxis or treatment of flavivirus infection or a disease resulting therefrom in humans or animals, characterised in that the composition comprises quercetin, or analogues, or derivatives thereof. The composition may further comprise a pharmaceutically acceptable carrier. The antiviral activity may include inhibition of virus attachment to host cells and inhibition of intracellular virus replication. The flavivirus may comprise dengue virus type-1, dengue virus type-2, dengue virus type-3, and dengue virus type-4.
    Type: Application
    Filed: January 31, 2013
    Publication date: March 19, 2015
    Inventor: Sazaly Abu Bakar
  • Publication number: 20150025131
    Abstract: Patuletin, a flavonoid isolated from Tagetes patula, was discovered to be a potent inhibitor of TNF-? production and thus useful in treating diseases related to TNF-? levels in the body.
    Type: Application
    Filed: July 17, 2013
    Publication date: January 22, 2015
    Inventors: Muhammed Ahmed Mesaik, Almas Jabeen, Shaheen Faizi, Shabana Usman Simjee, Samina Bano, Lubna
  • Publication number: 20150011618
    Abstract: The present invention is directed to chromenone compounds of formula (I), pharmaceutically acceptable salts, prodrugs thereof, and the composition comprising the compounds or the like. They can be used to modulating the function of estrogen receptor ER-?36 preventing and/or treating the estrogen related diseases, such as breast cancer, leukemia, liver cancer and etc.
    Type: Application
    Filed: December 31, 2012
    Publication date: January 8, 2015
    Applicant: BEIJING SHENOGEN PHARMA GROUP LTD.
    Inventors: Hongxia Ding, Jin Li, Kun Meng
  • Publication number: 20140357876
    Abstract: The present invention provides the use of Icaritin for the preparation of a composition for treating cancer, wherein the composition is orally administered to a patient at least one cycle, each cycle comprising a continuous 28-day dosing schedule, in which Icaritin is administered at least once daily, at a dosage of 400-1800 mg daily. The patients treated with Icaritin according to the present method receive better treatment, with reduced adverse effects.
    Type: Application
    Filed: May 30, 2014
    Publication date: December 4, 2014
    Applicant: BEIJING SHENOGEN PHARMA GROUP LTD.
    Inventors: Kun MENG, Hongxia DING, Shu LI, Ya TUO, Yueqiu SHEN
  • Publication number: 20140349866
    Abstract: Methods are described for using genes crucial in TH17 differentiation, IL-12Rbeta 1/IL-23R, CCR6, BATF, AHR, STAT3 and IRF4 as new markers for rosacea. Also described, are methods of their use to diagnose rosacea, to screen inhibitors of Th17 differentiation. In particular, method are described for inhibiting at least one of these genes and using the screened inhibitors in rosacea treatment.
    Type: Application
    Filed: June 25, 2012
    Publication date: November 27, 2014
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventor: Martin Steinhoff
  • Publication number: 20140341934
    Abstract: The invention is directed to a process for extracting materials from biological material, which process is characterized in that the naturally occurring biological material is treated with an extractant consisting of a deep eutectic solvent of natural origin or a an ionic liquid of natural origin to produce a biological extract of natural origin dissolved in the said solvent or ionic liquid.
    Type: Application
    Filed: August 5, 2014
    Publication date: November 20, 2014
    Inventors: Jacob van Spronsen, Geert-Jan Witkamp, Frank Hollman, Young Hae Choi, Robert Verpoorte
  • Publication number: 20140323745
    Abstract: A polyphenolic selenium compound having a functional group of alkali metal ion and selenium complex which has an aromatic ring is provided, wherein the aromatic ring comprises at least two functional groups, each of which is one member selected from the group consisting of oxygen functional group, sulphur functional group, phosphorus functional group and nitrogen functional group; and selenium complex functional group is formed by selenium, alkali metal ion and the functional group. The polyphenolic selenium compound having a functional group of alkali metal ion and selenium complex of the present invention has characteristics of over 20% selenium content and no toxicity. Because it has revolutionary effects in killing bacteria, virus and cancer cell, enhancing human immunity, removing oxygen free radicals and etc., it holds a vital medicinal value.
    Type: Application
    Filed: January 18, 2014
    Publication date: October 30, 2014
    Applicant: Shanghai Ai Qi Ecological Technology Co., Ltd.
    Inventors: Gong Chen, Kunyuan Song
  • Publication number: 20140303244
    Abstract: The invention provides methods, uses and compounds for treating cancers.
    Type: Application
    Filed: November 19, 2012
    Publication date: October 9, 2014
    Inventors: Ann M. Bode, Young-Yeon Cho, Zigang Dong, Dong Joon Kim
  • Publication number: 20140288286
    Abstract: The present invention relates to methods to isolate flavonoids from Euphorbia cuneata, and a pharmaceutical composition comprising the flavonoids or the extracts or both of them for a use as anti-ulcer agent. The present invention further relates to a method to isolate a compound selected from the group consisting of 4?-methoxy-luteolin-7-O-rhamnoglucoside and/or aromadendrin from Euphorbia cuneata.
    Type: Application
    Filed: June 5, 2014
    Publication date: September 25, 2014
    Inventors: Amani S. AWAAD, Reham Moustafa EL-MELIGY
  • Publication number: 20140275156
    Abstract: There is provided now flavonoid compounds, compositions containing these compounds, methods for their synthesis, and uses of these compounds. In particular, there is provided methods of preventing and or mitigating the damage caused by cell apoptosis or cell necrosis by administration of the novel flavonoid compounds. In some aspects, there is provided methods for inhibiting pro-apoptotic signalling kinases activity in a subject while regulating and activating extracelluar signal regulated kinase (ERK).
    Type: Application
    Filed: August 13, 2012
    Publication date: September 18, 2014
    Applicant: NEUPROTECT PTY LTD
    Inventor: Grant McLachlan
  • Publication number: 20140248383
    Abstract: An object is to provide a sleep quality improving agent that can sufficiently exert the effect of improving the quality of sleep and ensures safety for the body. A sleep quality improving agent containing, as an effective ingredient, a plant of the Fraxinus genus such as Fraxinus excelsior L., an extract thereof, Larix sibirica extract, dihydroquercetin, dihydrokaempferol, or naringenin, and a sleep quality improving composition containing the sleep quality improving agent are provided.
    Type: Application
    Filed: October 9, 2012
    Publication date: September 4, 2014
    Applicant: LION CORPORATION
    Inventors: Yoshihiro Urade, Toshio Gokita, Ikuko Kamada, Kiwamu Suzuki, Michiaki Murakoshi
  • Publication number: 20140221319
    Abstract: The invention provides methods and compositions for inhibiting CD 38 activity, and methods of treating or preventing various disorders associated with CD38 activity.
    Type: Application
    Filed: April 13, 2012
    Publication date: August 7, 2014
    Applicants: Mayo Foundation for Medical Education and Research, President and Fellows of Harvard College
    Inventors: David A. Sinclair, Nathan L. Price, Eduardo N. Chini, Jon C. Clardy, Shugeng Cao
  • Publication number: 20140186328
    Abstract: The present invention provides neuroprotective polyphenol compounds, which can be synthetic analogs of fisetin, baicalein or chlorogenic acid, that maintain neuroprotective, anti-inflammatory, glutathione promoting, and/or antioxidant properties. The neuroprotective polyphenol compounds are useful for promoting, enhancing and/or increasing neuron protection, growth and/or regeneration. The polyphenol compounds further find use for increasing and or maintaining intracellular glutathione (GSH) levels. The polyphenol compounds are also useful for treating, preventing, mitigating and/or delaying neurodegenerative conditions, including diabetes, Parkinson's disease, Huntington's disease, Alzheimer's disease, non-Alzheimer's dementias, multiple sclerosis, traumatic brain injury, spinal cord injury or ALS.
    Type: Application
    Filed: February 5, 2014
    Publication date: July 3, 2014
    Applicant: Salk Institute for Biological Studies
    Inventors: David R. Schubert, Pamela A. Maher, Chandramouli Chiruta
  • Patent number: 8759546
    Abstract: The present invention discloses a physical nano-complex for preventing and treating cancer and a method for manufacturing the same. The composition contains EGCG and nanogold, wherein the ratio of the EGCG to the nanogold is in a range from 23:0.5˜23:10 (ppm/ppm). The present invention further discloses a method for manufacturing the composition, wherein the method is to mix the EGCG and the nanogold sufficiently by an ultrasonication process, which makes the EGCG and the nanogold combine to each other well.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: June 24, 2014
    Assignee: Gold Nanotech Inc.
    Inventors: Shan-Wen Tan, Ming-Kung Yeh, Dar-Shih Hsieh, Chang-Jer Wu
  • Publication number: 20140141510
    Abstract: The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.
    Type: Application
    Filed: April 10, 2012
    Publication date: May 22, 2014
    Applicants: MEDIZINISCHE HOCHSCHULE HANNOVER, HELMHOLTZ ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH
    Inventors: Lars Zender, Torsten Wuestefeld
  • Patent number: 8716497
    Abstract: A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: May 6, 2014
    Assignees: Children's Hospital Medical Center, Ausio Pharmaceuticals, Inc.
    Inventors: Kenneth David Reginald Setchell, Victor Dmitrievich Sorokin
  • Patent number: 8709745
    Abstract: The present invention relates to agonists and antagonists of the human bitter-taste receptor hTAS2R49. The invention also relates to methods for identifying further molecules that suppress or enhance hTAS2R49-mediated bitter taste transduction or bitter taste response and uses thereof.
    Type: Grant
    Filed: July 28, 2010
    Date of Patent: April 29, 2014
    Assignee: Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke
    Inventors: Claudia Batram, Wolfgang Meyerhof
  • Publication number: 20140096780
    Abstract: Isolated O-methylated flavonoid compounds and mixtures of o-methylated flavonoid compounds derived from a plant of the Nicotiana species and methods of obtaining such compounds are provided. The o-methylated flavonoids can be combined with tobacco materials to produce tobacco products (e.g., smoking articles) to enhance the sensory characteristics thereof. The o-methyl flavonoids can alternatively be combined with non-tobacco materials for dietary supplement and/or pharmaceutical use.
    Type: Application
    Filed: October 9, 2012
    Publication date: April 10, 2014
    Applicant: R.J. REYNOLDS TOBACCO COMPANY
    Inventor: Anthony Richard Gerardi
  • Patent number: 8658237
    Abstract: The object of the present invention is to provide an anti-obesity agent which contains a tea-derived component and which is safe and does not compromise the flavor of foods and beverages. According to the present invention, a safe and palatable anti-obesity agent can be provided by incorporating a benzotropolone ring-containing compound which has tea-derived, high inhibitory activities against lipase and alfa-glucosidase. The anti-obesity agent of the present invention does not compromise the flavor of foods and beverage, has palatability, and can be used in various use applications including foods and beverages intended for health enhancement such as reduction in triglycerides.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: February 25, 2014
    Assignee: Suntory Holdings Limited
    Inventors: Yuko Fukui, Sumio Asami, Mitsuru Maeda
  • Publication number: 20140031421
    Abstract: The present invention provides synthetic processes for preparing racemic and/or optically pure epicatechin, epigallocatechin and related polyphenols as such or as their variously functionalized derivatives. A principle objective of the disclosure is to provide a new and useful method of synthesis to obtain polyphenols in isomerically pure and/or racemic forms.
    Type: Application
    Filed: January 24, 2012
    Publication date: January 30, 2014
    Applicant: SPHAERA PHARMA PTE. LTD.
    Inventors: Sundeep Dugar, Dinesh Mahajan, Pantelis Peter Giannousis, Vijay Singh, Kamal Kishore Kapoor
  • Patent number: 8629197
    Abstract: A chemically patterned modified hydrogel formed from a modified hydrogel is provided. The hydrogel is conjugated with a multiphoton photocleavable molecule. The molecule has a multiphoton-labile protective group and a protected group. The protective group is cleavable upon multiphoton excitation to deprotect the protected group, without substantial polymerization of the hydrogel. The chemically patterned modified hydrogel is formed by exposing the modified hydrogel to multiphoton excitation to deprotect a portion of the protected groups.
    Type: Grant
    Filed: April 7, 2008
    Date of Patent: January 14, 2014
    Inventors: Molly Shoichet, Jordan Wosnick, Ryan Wylie
  • Publication number: 20130303544
    Abstract: The present invention provides a kind of benzopyrone compounds having a structure of formula (I) and the pharmaceutically acceptable salts or prodrugs thereof, and the pharmaceutical compositions containing such compounds, which can be used to regulate the novel estrogen receptor ER-a36, and prevent and/or treat the related diseases mediated by the ER-a36 receptor, such as cancers, etc.
    Type: Application
    Filed: December 21, 2011
    Publication date: November 14, 2013
    Applicant: BEIJING SHENOGEN PHARMA GROUP LTD.
    Inventors: Hongxia Ding, Kun Meng, Jin Li
  • Patent number: 8575368
    Abstract: This invention provides useful applications of cashew apple. This invention also provides a naturally occurring active ingredient having useful activities, such as alpha-amylase inhibitory activity, lipase inhibitory activity, and antibacterial activity against Propionibacterium acnes. The invention also provides a composition containing cashew apple-derived proanthocyanidin having excellent alpha-amylase inhibitory activity, lipase inhibitory activity, and antibacterial activity against Propionibacterium acnes, which is prepared by allowing a plant fiber-degrading enzyme (e.g., pectinase) to react with a cashew apple and concentrating the resultant with the use of an ultrafiltration membrane. Further, the invention provides a proanthocyanidin compound having a novel structure.
    Type: Grant
    Filed: June 25, 2009
    Date of Patent: November 5, 2013
    Assignee: Nichirei Biosciences, Inc.
    Inventor: Kenichi Nagamine
  • Publication number: 20130281717
    Abstract: The invention relates to the chemical and pharmaceutical industry. The essence of the invention consists in that the bark is removed from Siberian or Dahurian larch wood, the wood is chopped and dried at 40-50° C. to a residual humidity of 15-25 percent. The dried wood is ground, and the soluble substances are extracted from the sawdust using a 75 percent aqueous solution of ethyl alcohol at a temperature of 40-50° C. with a ratio of raw material to extraction agent of 1:(6-7). The extraction agent is then distilled off, and the aqueous portion of the extract is cooled to 38-42° C. over a period of 20-30 minutes for the removal (sedimentation) of the heavy resinous impurities accompanying the DHQ. The resin-free aqueous DHQ extract is fed into a chromatographic column filled with the hydrophobic polyvinyl benzene-based sorbent LPS 500. The desired product is eluted with a 32-40 percent solution of ethyl alcohol.
    Type: Application
    Filed: November 9, 2011
    Publication date: October 24, 2013
    Inventors: Vladimir Sergeevich Ostronkov, Sergej Alekseevich Lashin
  • Publication number: 20130281525
    Abstract: Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.
    Type: Application
    Filed: July 27, 2011
    Publication date: October 24, 2013
    Applicants: TRUSTEES OF BOSTON UNIVERSITY, BOSTON MEDICAL CENTER CORPORATION, NORTHEASTERN UNIVERSITY
    Inventors: David H. Sherr, Michael Pollastri, Jennifer Schlezinger, Sarah Haigh Molina, Scott Schaus, Joshua Robert Giguere
  • Publication number: 20130267586
    Abstract: The present invention provides compounds of the formula Formula I or a salt thereof: and the uses of such compounds for the treatment of a disease or disorder involving oxidative damage, for preventing UV damage to the skin of a mammal and for preventing or reversing the effects of ageing, or for treating or preventing dry skin.
    Type: Application
    Filed: October 13, 2011
    Publication date: October 10, 2013
    Applicant: ANTOXIS LIMITED
    Inventors: Donald Barton McPhail, Graeme James Cook, Richard Charles Hartley
  • Publication number: 20130237712
    Abstract: A method for isolating flavonoid Dihydroquercetin (taxifolin) from wood parts including lower portions of the trunk, referred to as butt logs, bark and roots. The method includes extracting either the particle-reduced chip fraction obtained by chipping or subdividing into chips the butt logs and roots, or dry cork fraction of the bark or powdered bark obtained as a residue in finishing of mechanical wood products with a polar solvent. The method further includes recovering the extract. The wood used in the method is a hardwood or a coniferous wood selected from wood of Larix genus, spruce wood of the genus Picea, fir wood of the genus Abies, pine wood of the genus Pinus, and wood of Pseudotsuga genus. The isolated prime substance from all of the above genus is a flavonoid such as Dihydroquercetin (taxifolin).
    Type: Application
    Filed: March 12, 2012
    Publication date: September 12, 2013
    Applicant: FLAVITPURE, INC.
    Inventors: Sergey V. Philippov, Igor M. Bogorodov
  • Publication number: 20130210907
    Abstract: The present invention provides methods and compositions for preventing or treating enterochromatffin cell hyperplasia-related diseases. The compositions comprise a therapeutic effective amount of Quercetin, glycosylated Quercetin, or mixture thereof.
    Type: Application
    Filed: February 14, 2013
    Publication date: August 15, 2013
    Applicant: HONG KONG BAPTIST UNIVERSITY
    Inventor: HONG KONG BAPTIST UNIVERSITY
  • Publication number: 20130171271
    Abstract: Methods for treating cancers, tumors, and neoplasms using a composition comprising one or more generally regarded as safe (GRAS) compounds selected from the group of components consisting of vitamins, selenium, fatty acids, fatty acid salts, and fatty acid esters, and mixtures of two or more said components, either as a stand-alone treatment or in combination with one or more anti-cancer drugs or devices or other anti-neoplastic agents, treatments, or devices are provided. In some instances, concomitant hyperthermia therapy is employed. Also provided are compositions and kits containing the compositions, for implement various aspects of the invention.
    Type: Application
    Filed: July 25, 2011
    Publication date: July 4, 2013
    Applicant: CHEMOTHERAPEUTICS, LLC
    Inventors: Gary Keeling, Keith B. Hoffman
  • Patent number: 8476313
    Abstract: Compounds and methods useful for treating and prevention of cancer, particularly hormone-dependent breast cancer. Provided are compounds of formula I: wherein X is selected from O, N, S, SO, SO2, and S(CH2)n, wherein n=1-10; R1 and R2 may be the same or different and are selected from H, OH, OCH3, OCH2CH3, OCH2C6H5, NH2, NHCH3, N(CH3)2, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, C(CH3)3, NO2, F, Cl, Br, CF3, SH, SCH3, SCH2CH3, OCOCH3, OCOC(CH3)3, OCOCH2COOH, and CN; and R3 is a nitrogen-containing heterocyclic ring. Also provided are method for treating or preventing cancer in a subject by administering a therapeutically effective amount of a heteroaryl-containing isoflavone, or a pharmaceutically acceptable salt or prodrug thereof, to a subject in need of treatment.
    Type: Grant
    Filed: May 26, 2009
    Date of Patent: July 2, 2013
    Assignee: The Ohio State University Research Foundation
    Inventors: Robert W. Brueggemeier, Young-Woo Kim, John C. Hackett
  • Publication number: 20130149322
    Abstract: The invention is directed to a process for extracting materials from biological material, which process is characterized in that the naturally occurring biological material is treated with an extractant consisting of a deep eutectic solvent of natural origin or a an ionic liquid of natural origin to produce a biological extract of natural origin dissolved in the said solvent or ionic liquid.
    Type: Application
    Filed: June 7, 2011
    Publication date: June 13, 2013
    Applicant: UNIVERSITEIT LEIDEN
    Inventors: Jacob van Spronsen, Geert-Jan Witkamp, Frank Hollman, Young Hae Choi, Robert Verpoorte
  • Publication number: 20130137762
    Abstract: This invention relates to extracts and refined fractions of a traditional Chinese medicinal herb, Alpinia officinarum (AO), components thereof, and the use of such compounds and compositions to treat neurodegenerative or neuropathological conditions or to inhibit aggregation of a-synuclein.
    Type: Application
    Filed: August 10, 2011
    Publication date: May 30, 2013
    Applicant: THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Nancy Yuk Yu Ip, Kenny Ka Kin Chung, Fanny Chui Fun Ip, Guangmiao Fu
  • Publication number: 20130133108
    Abstract: The present disclosure provides methods of making and using plant extracts that include quercetin, which are generated from transgenic plants that have decreased pirin activity (prn-). Such transgenic plants and their extracts can be used to increase tolerance of a plant to a stressor, such as UV light, as well as treat tumor cells (such as kill cancer cells), prevent certain types of fungal infections (such as C. gattii), and increase antioxidant activity. The present disclosure also provides methods of making and using plant extracts that are depleted of quercetin, which are generated from transgenic plants that have increased pirin activity (prn+). Such transgenic plants and their extracts can be used to prevent certain types of fungal infections (such as C. neoformans). Also provided are compositions that include the prn- or prn+ extracts, such as a plastic coated with the extract.
    Type: Application
    Filed: August 25, 2011
    Publication date: May 23, 2013
    Inventors: Katherine Warpeha, Lon Kaufman
  • Publication number: 20130096209
    Abstract: The present invention provides edible compositions comprising a compound of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of NaCl in a food product, methods of reducing the sodium intake in a diet, and methods of reducing bitter taste in a food product.
    Type: Application
    Filed: April 15, 2011
    Publication date: April 18, 2013
    Applicants: Kraft Foods Global Brands LLC, Chromocell Corporation
    Inventors: David Hayashi, William P. Jones, Jane V. Leland, Peter H. Brown, Joseph Gunnet, Daniel Lavery, Louise Slade, Kambiz Shekdar, Jessica Langer
  • Publication number: 20130066048
    Abstract: Described herein is an enriched substance containing a ground edible material comprising one or more concentrated bioactive natural products from plant juice, as well as methods of producing such enriched substances and methods of using such solids to provide beneficial effects to humans or other animals. Enriched foods comprising the enriched substance(s) are also provided. Also provided are non-sorbed natural products such as sugars, fats oils, and carotenoids found in the non-sorbed plant liquor fraction of plant juice.
    Type: Application
    Filed: March 14, 2011
    Publication date: March 14, 2013
    Applicant: Rutgers, The State University of New Jersey
    Inventors: Ilya Raskin, Diana Roopchand, Slavko Komarnytsky
  • Publication number: 20130059384
    Abstract: Compositions and methods comprising bioenergetic agents for restoring the quality of aged oocytes, enhancing oogonial stem cells or improving derivatives thereof (e.g., cytoplasm or isolated mitochondria) for use in fertility-enhancing procedures, are described.
    Type: Application
    Filed: April 13, 2012
    Publication date: March 7, 2013
    Applicants: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE GENERAL HOSPITAL CORPORATION
    Inventors: JONATHAN L. TILLY, DAVID A. SINCLAIR
  • Patent number: 8378044
    Abstract: Provided is a low-cost, environmentally friendly living radical polymerization catalyst having high activity. The catalyst is used for a living radical polymerization method, and contains a central element consisting of oxygen and at least one halogen atom bound to the central element. Furthermore, an alcohol compound can be used as a catalyst precursor. By polymerizing a monomer in the presence of the catalyst, a polymer having narrow molecular weight distribution can be obtained, and the cost of the living radical polymerization can be remarkably reduced. The present invention is significantly more environmentally friendly and economically excellent than conventional living radical polymerization methods, due to advantages of the catalyst such as low toxicity of the catalyst, low amount of the catalyst necessary, high solubility of the catalyst, mild reaction conditions, and no coloration/no odor (which do not require a post-treatment for a molded article), and the like.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: February 19, 2013
    Assignee: Kyoto University
    Inventors: Atsushi Goto, Takeshi Fukuda, Yoshinobu Tsujii
  • Publication number: 20130035304
    Abstract: This invention relates to compounds which selectively bind to the survival protein MCL-1 with high affinity and selectivity, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for modulating MCL-1 activity and for treating hyperproliferative disorders, angiogenesis disorders, cell cycle regulation disorders, autophagy regulation disorders, inflammatory disorders, and/or infectious disorders and/or for enhancing cellular engraftment and/or wound repair, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: January 31, 2011
    Publication date: February 7, 2013
    Inventors: Loren D. Walensky, Michelle L. Stewart, Nicole Cohen
  • Publication number: 20130028837
    Abstract: The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.
    Type: Application
    Filed: August 10, 2012
    Publication date: January 31, 2013
    Applicant: Lantheus Medical Imaging, Inc.
    Inventors: Heike S. Radeke, David S. Casebier, Michael T. Azure, Douglas D. Dischino
  • Publication number: 20120323016
    Abstract: The present invention relates to the preparation of a class of novel, optically active compounds derived from oligomeric proanthocyanidins (OPCs), more particularly to oligomers of epicatechin. These compounds include multidentate ligands and their metal complexes for use in catalysis. Methods of depolymerising proanthocyanidins to form catechins, and particularly depolymerising proanthocyanidins derived from plant sources to form novel epicatechins having application in catalysis are disclosed.
    Type: Application
    Filed: December 17, 2010
    Publication date: December 20, 2012
    Applicant: NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Dejian Huang, Wei Chen, Runyun Ni, Caili Fu, Yi Ling Quek
  • Publication number: 20120283322
    Abstract: The present invention relates to Rhus verniciflua Stokes extract having an increased content of an active flavonoid compound through a gas bubbling treatment, a method for preparing the Rhus verniciflua Stokes extract, and a method for converting fustin into fisetin through the gas bubbling treatment of a solution containing fustin. The method for preparing the Rhus verniciflua Stokes extract of the present invention can convert the conventional Rhus verniciflua Stokes extract having high content of fustin and low content of fisetin into a Rhus verniciflua Stokes extract having high content of fisetin. Therefore, the Rhus verniciflua Stokes extract of the present invention can be commercialized into natural anticancer agents, anticancer and cancer prevention food products, and health functional foods due to the excellent bioactivity thereof, and promote the development of relevant industries through the high added-value of Rhus verniciflua Stokes.
    Type: Application
    Filed: December 27, 2010
    Publication date: November 8, 2012
    Applicant: AZI COMPANY LTD.
    Inventors: Sang-Jae Park, Kyung-Hee Kim, Myung-Jae Shin, Sang-Seok Lee, Byung-Sik Kang, Won-Cheol Choi, Sung-Pil Kwon
  • Publication number: 20120264820
    Abstract: A compound, pharmaceutical composition and method for the treatment of mammals wherein the active therapeutic agent is a compound having the structure: wherein: R1 is an electronegative substituent, R2 is R1 or alkyl, R3 is H or O-alkyl, R4 and R5 are the same or different and are alkyl and R6 is H or OH.
    Type: Application
    Filed: December 31, 2007
    Publication date: October 18, 2012
    Inventors: Kinfe Redda, Chavonda Janeebra Mills, Nelly Maleeva
  • Publication number: 20120258170
    Abstract: A co-crystal composition comprised of Quercetin and at least one antidiabetic agent acts as a combination drug having unique physical properties and biological activity, which differ from both Quercetin in pure form and the at least one antidiabetic agent in pure form. The co-crystal composition may comprise quercetin and metformin. The co-crystals of quercetin and metformin may be prepared by grinding the compounds, and used in pharmaceutical compositions comprising these co-crystals. Co-crystal compositions of quercetin and Metformin may be used in combination with other anti-diabetic agents, including DPP-IV inhibitors.
    Type: Application
    Filed: March 19, 2012
    Publication date: October 11, 2012
    Applicant: Nutracryst Therapeutics Private Limited
    Inventors: Anil Kumar KRUTHIVENTI, Iqbal Javed, Satyanarayana Reddy Jaggavarapu, RaviKumar Nagalapalli, Ganesh Saraswatula Viswanadha, Solomon Kamalakaran Anand